Expression of microRNA-132 in peripheral blood of patients with pancreatic cancer and its clinical significance
Objective To study the expression of microRNA-132 in peripheral blood of patients with pancreatic cancer and its clinical significance.Methods 83 patients with pancreatic cancer were selected as the observation group,and 50 patients with pancreatitis and 50 healthy subjects were selected as the control group Ⅰand control group Ⅱ.All study subjects were extracted microRNA-132 from cells by Trizol method and reverse-transcribed into cDNA by reverse transcription kit.A reaction system was prepared according to the instructions of the real-time quantitative polymerase chain reaction(RT-qPCR)kit for amplification,and the relative expression level of microRNA-132 was calculated.The relative expression levels of microRNA-132 in the three groups were compared to analyze the diagnostic value of relative expression of micro RNA-132 for pancreatic cancer.Results(i)The relative expression level of microRNA-132 was compared among the three groups,and the difference was statistically significant(P＜0.05).The relative expression level of microRNA-132 in peripheral blood of the observation group was(2.87±0.60),which was significantly higher than(2.50±0.52)of the control group Ⅰ and(2.02±0.42)of the control group Ⅱ;the control group Ⅰ was higher than the control group Ⅱ;the difference was statistically significant(P＜0.05).(ii)Receiver operating characteristic(ROC)curve showed that the optimal threshold for the diagnosis of pancreatic cancer by micro RNA-132 was 2.79;the relative expression level of microRNA-132 in peripheral blood reached 2.79,and its area under the curve(AUC)for the diagnosis of pancreatic cancer was 0.907,95%CI =(0.864,0.949),with a sensitivity of 79.50%and a specificity of 90.00%,P＜0.05.Conclusion There is a significant trend of upregulation of microRNA-132 in the peripheral blood of patients with pancreatic cancer,and microRNA-132 can be used as a primary marker for the potential diagnosis of patients with pancreatic cancer.
NETL
NSTL
万方数据
维普
